Armata gets FDA Breakthrough status for AP-SA02 therapy
Rhea-AI Filing Summary
Armata Pharmaceuticals, Inc. (ARMP) reports that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to AP-SA02, its intravenously administered multi-phage product candidate, for adjunct treatment of complicated Staphylococcus aureus bacteremia caused by MSSA or MRSA. The designation is supported by the Phase 1b/2a diSArm study, in which AP-SA02 plus best available antibiotic therapy given every six hours for five days was well tolerated and showed higher and earlier clinical cure rates than placebo plus best available therapy. At the end-of-study assessment, 28 days after completion of antibiotics, 100% of AP-SA02 patients maintained clinical response without relapse versus 75% on placebo, with favorable trends in biomarkers such as CRP and IL-10. AP-SA02 now holds Breakthrough Therapy, Fast Track and QIDP designations, and its development, including Phase 3 readiness, is partially supported by a $28.7 million Department of War award, with a Phase 3 superiority study in complicated SAB planned to begin in the second half of 2026.
Positive
- FDA Breakthrough Therapy designation for AP-SA02, on top of existing Fast Track and QIDP, materially strengthens the regulatory path for Armata’s lead asset in complicated Staphylococcus aureus bacteremia.
- Phase 1b/2a diSArm data show 100% of AP-SA02 patients relapse-free vs. 75% on placebo at 28 days post-therapy, with good tolerability, supporting advancement into Phase 3.
- AP-SA02 development and Phase 3 preparation are partially backed by a $28.7 million Department of War award, reducing funding burden for this pivotal program.
Negative
- None.
Filing Explained
AP-SA02 gains enhanced FDA development support, but remains pre-approval and still requires the planned Phase 3 program.
The company reports that the FDA granted AP-SA02 Breakthrough Therapy designation for adjunct treatment of complicated Staphylococcus aureus bacteremia. The candidate remains in development and Phase 3 is only anticipated, so this is a regulatory-development milestone rather than an approval.
The designation is intended to expedite development and review and adds comprehensive FDA collaboration and senior-manager involvement to Fast Track features.
8-K Event Classification
Key Figures
Key Terms
Breakthrough Therapy designation regulatory
Qualified Infectious Disease Product regulatory
Fast Track designation regulatory
bacteriophage therapeutics medical
C-reactive protein medical
superiority study medical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Armata Pharmaceuticals (ARMP) announce regarding AP-SA02?
Why is the FDA Breakthrough Therapy designation important for ARMP’s AP-SA02?
What Phase 2 results for AP-SA02 did Armata (ARMP) highlight?
What other FDA designations does AP-SA02 have besides Breakthrough Therapy?
How is Armata’s planned Phase 3 program for AP-SA02 being supported financially?
When does Armata (ARMP) expect to start the Phase 3 study of AP-SA02?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact name of Registrant as specified in its charter)
| (State or other jurisdiction of incorporation or organization) |
(Commission File Number) | (IRS Employer Identification No.) |
| | |||
| (Address of principal executive offices) | (Zip Code) |
(
(Registrant’s Telephone number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered | ||
| Item 7.01 | Regulation FD Disclosure. |
On September 14, 2026, Armata Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to AP-SA02, the Company’s intravenously administered Staphylococcus aureus (“S. aureus”) multi-phage product candidate, for the adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus or methicillin-resistant S. aureus. The full text of the press release issued in connection with this announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 7.01 and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 7.01 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. |
Description | |
| 99.1 | Press Release, dated September 14, 2026. | |
| 104 | Cover Page Interactive Data File (embedded within Inline XBRL document). |
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: September 14, 2026 | Armata Pharmaceuticals, Inc. | |
| By: | /s/ David House | |
| Name: | David House | |
| Title: | Chief Financial Officer | |
- 3 -
Exhibit 99.1
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
Designation is driven by compelling Phase 2 clinical data in patients with complicated Staphylococcus aureus bacteremia showing AP-SA02 may offer substantial improvement over available therapies
Potentially accelerating the path to market for this innovative antibacterial treatment
AP-SA02 now holds Breakthrough Therapy, Fast Track and QIDP designations, providing strong regulatory validation
LOS ANGELES, Calif., September 14, 2026 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the U.S. Food and Drug Administration (the “FDA”) has granted Breakthrough Therapy designation to AP-SA02, the Company’s intravenously administered Staphylococcus aureus (“S. aureus”) multi-phage product candidate, for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus (“MSSA”) or methicillin-resistant S. aureus (“MRSA”). Breakthrough Therapy designation is intended to expedite the review of medicines that treat a serious or life-threatening condition and have shown preliminary clinical evidence indicating the potential for substantial improvement over available therapies.
“The decision by the FDA to grant Breakthrough Therapy designation to AP-SA02, in addition to Qualified Infectious Disease Product (“QIDP”) and Fast Track designations, recognizes the urgent need for new treatment options for patients with complicated S. aureus bacteremia (“SAB”), including MRSA, where many outcomes remain poor despite current standard-of-care,” said Dr. Deborah Birx, Chief Executive Officer of Armata. “Based on the Phase 2 clinical trial data, we believe AP-SA02 has the potential to represent an important advancement in the treatment of complicated SAB, a serious bloodstream infection that continues to be associated with significant relapse rate, morbidity and mortality. If ultimately confirmed in Phase 3 and approved, AP-SA02 has the potential to become the first antibacterial therapy approved based on superiority to current standard-of-care treatment in this patient population. We are grateful for the FDA’s enhanced engagement and are committed to working closely with the Agency to efficiently advance the development and review of AP-SA02, with the goal of bringing this potential new treatment option to patients as quickly as possible.”
Critically, the Breakthrough Therapy designation is supported by data from the successful Phase 1b/2a diSArm study in adults with complicated SAB. Armata’s proprietary purification process yielded the production of a high-purity, high-titer AP-SA02 drug product formulation enabling repetitive dose intravenous administration every six hours for five days. This dosing regimen was well tolerated with no serious adverse events attributed to AP-SA02, and, when added to best available antibiotic therapy (“BAT”) demonstrated higher and earlier clinical cure rates than placebo plus BAT. At the end-of-study assessment, 28 days after completion of BAT, 100% of patients treated with AP-SA02 maintained clinical response without relapse, compared with 75% of patients receiving placebo. Patients treated with AP-SA02 also demonstrated favorable trends across multiple measures of disease resolution, including more rapid normalization of C-reactive protein (CRP) and Interleukin-10 (IL-10), biomarkers associated with mortality risk and complications in SAB.
About Breakthrough Therapy Designation
Breakthrough Therapy designation is a program designed by the FDA to expedite the development and review of therapies that are intended to treat a serious or life-threatening condition where preliminary clinical evidence indicates potential substantial improvement over available therapies on a clinically significant endpoint. A Breakthrough Therapy is eligible for all features of Fast Track designation, in addition to comprehensive, cross-disciplinary collaboration with the FDA to design the most efficient clinical development program, and organizational commitment from senior FDA managers to expedite development and review.
About AP-SA02
Armata is developing AP-SA02, a fixed multi-phage cocktail, for the adjunct treatment of complicated Staphylococcus aureus bacteremia caused by methicillin-sensitive S. aureus (MSSA) or methicillin-resistant S. aureus (MRSA). AP-SA02 has received Qualified Infectious Disease Product (QIDP) designation, Fast Track designation, and Breakthrough Therapy designation from the FDA. The diSArm study (NCT05184764) was a Phase 1b/2a, multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose escalation study of the safety, tolerability, and efficacy of intravenous AP-SA02 in addition to best available antibiotic therapy (“BAT”) compared to BAT alone (placebo) for the treatment of adults with complicated S. aureus bacteremia. Positive results from the Phase 2a diSArm study were highlighted in a late-breaking oral presentation at IDWeek 2025™ in October 2025. The Phase 1b/2a clinical development of AP-SA02, and activities related to End-of-Phase 2 and Armata’s preparation and readiness for its planned Phase 3 clinical study, is partially supported by a $28.7 million Department of War (DoW) award, received through the Medical Technology Enterprise Consortium (MTEC) and managed by the Naval Medical Research Command (NMRC) – Naval Advanced Medical Development (NAMD) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. The Company plans to advance AP-SA02 into a Phase 3 superiority study in complicated SAB, anticipated to initiate in the second half of 2026.
About Armata Pharmaceuticals, Inc.
Armata is a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other important pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific current Good Manufacturing Practices (“cGMP”) manufacturing to support full commercialization.
Forward Looking Statements
This communication contains “forward-looking” statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to Armata’s future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata’s actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, and similar expressions. These forward-looking statements reflect management’s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks related to Armata’s development of bacteriophage-based therapies; Armata’s planned clinical trials; ability to staff and maintain its production facilities under fully compliant cGMP; ability to meet anticipated milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata’s estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption “Risk Factors” and elsewhere in Armata’s filings and reports with the U.S. Securities and Exchange Commission (the “SEC”), including in Armata’s Annual Report on Form 10-K, filed with the SEC on March 25, 2026, and in its subsequent filings with the SEC.
Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Media Contacts:
At Armata:
Pierre Kyme
ir@armatapharma.com
310-665-2928
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569